Back to Results
First PageMeta Content



FINAL Catabasis Pharmaceuticals Announces the Initiation of an Open-Label Extension for the MoveDMD® Trial Studying Edasalonexent (CATin Duchenne Muscular Dystrophy CAMBRIDGE, MA, July 7, 2016 – Catabasis Phar
Add to Reading List

Document Date: 2016-07-07 08:01:15


Open Document

File Size: 40,15 KB

Share Result on Facebook
UPDATE